You can’t go anywhere today without hearing about GLP1-s like Wegovy and Ozempic – whether it’s in your social circle, headlines on the news, or celebrities and influencers talking about their experience with these “miracle” weight-loss drugs.  

And while they are certainly effective, these medications come at a cost. In fact, research forecasts that the GLP-1 market is expected to exceed $100 billion by 2030, driven equally by diabetes and obesity treatment.

In this episode of Health Unscripted, Tim Harlan, vice president of account management for health plans at Express Scripts by Evernorth, sits down with Dr. Gerry Stanley, chief medical officer, and Ashley Holzworth-Nash, vice president of retail network product strategy and solutions for a deep dive into the challenges and opportunities within the GLP-1 landscape.

Tune in to learn about:

• GLP-1 dilemmas that span the entire health care ecosystem
• The need for action within the GLP-1 supply chain to ensure patient access
• Ways to support better patient outcomes